Nicotine Vaccine
Nicotine conjugate vaccine elicits dose-related immunogenicity in tobacco smokers
Published in Vaccine Weekly, January 18th, 2006
"Immunotherapy is a novel potential treatment for nicotine addiction. The aim of [our] study was to assess the safety and immunogenicity of a nicotine conjugate vaccine, NicVAX, and its effects on smoking behavior," investigators in the United States report.
According to D.K. Hatsukami and colleagues at the University of Minnesota, "Smokers (N=68) were recruited for a noncessation treatment study and assigned to 1 of 3 doses of the nicotine vaccine (50, 100, or 200 mcg) or placebo. They were injected on days 0, 28, 56, and 182 and monitored for a period of 38...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2006-01-18)
More Articles from Vaccine Weekly
- Diabetes Vaccine
Protein Sciences to produce diabetes vaccine for phase III trials - HIV/AIDS Vaccine
Recombinant canarypox vaccine is safe and immunogenic in HIV-1-exposed newborns - Influenza A Virus
Improved influenza A virus generation may improve vaccine production - West Nile Virus
West Nile vaccine begins Phase I clinical study - Anthrax
U.S. FDA rules anthrax vaccine safe - Anthrax Toxin
Anthrax toxins directly inhibit T-lymphocyte activation - More from this issue of Vaccine Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
